We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Research in ALS Study (CRiALS)

This study is currently recruiting participants.
Verified June 2017 by Michael Benatar, University of Miami
Sponsor:
ClinicalTrials.gov Identifier:
NCT00136500
First Posted: August 29, 2005
Last Update Posted: June 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
ALS Association
ALS Recovery Fund
Information provided by (Responsible Party):
Michael Benatar, University of Miami
  Purpose
CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).

Condition
Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Prospective
Official Title: Clinical Research in ALS

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Michael Benatar, University of Miami:

Primary Outcome Measures:
  • Recruitment [ Time Frame: Annually ]
    Since this is an umbrella/gateway protocol through which individuals are recruited to participate in a range of studies, outcome is assessed in terms of recruitment.


Biospecimen Retention:   Samples With DNA
DNA, blood, urine, CSF, skin biopsies

Estimated Enrollment: 10000
Study Start Date: February 2005
Estimated Study Completion Date: December 2027
Estimated Primary Completion Date: December 2027 (Final data collection date for primary outcome measure)
Detailed Description:
Research goals include elucidation of the complex relationship between ALS and related neurodegenerative disorders, development of both wet and dry biomarkers of disease, and delineation of the full course of the natural history of disease from the early pre-symptomatic stages through established and even late-stage disease. These goals are accomplished through the recruitment and evaluation of patients with ALS and related diseases, family members (including people at genetic risk for ALS, but who are not yet affected), and healthy controls.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The CRiALS research program aims to recruit three types of participants:

  • Individuals affected with ALS or a related neurodegenerative disease
  • Unaffected individuals from pedigrees in which the genetic cause of ALS is known
  • Healthy controls
Criteria

Inclusion Criteria:

  1. At least 18 years of age.

  2. Member of at least one of the following categories:

    1. Individuals affected with ALS or a related neurodegenerative disease (sporadic or familial)
    2. Unaffected individuals from fALS pedigrees, including pre-symptomatic individuals at genetic risk for ALS or individuals from pedigrees of ALS related diseases.
    3. Healthy controls
  3. Able and willing to comply with relevant procedures.

Exclusion Criteria:

Subject has a condition or is in a situation which, in the PI's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol -- including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00136500


Contacts
Contact: Eliana Reyes 888-413-9315 fals@med.miami.edu
Contact: Danielle Dauphin 888-413-9315 fals@med.miami.edu

Locations
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Eliana Reyes    888-413-9315    fals@med.miami.edu   
Sponsors and Collaborators
Michael Benatar
ALS Association
ALS Recovery Fund
Investigators
Principal Investigator: Michael Benatar, MD, PhD. University of Miami
  More Information

Additional Information:
ALS Research Collaboration  This link exits the ClinicalTrials.gov site

Responsible Party: Michael Benatar, MBChB, MS, DPhil, University of Miami
ClinicalTrials.gov Identifier: NCT00136500     History of Changes
Other Study ID Numbers: FALS feasibility
First Submitted: August 25, 2005
First Posted: August 29, 2005
Last Update Posted: June 9, 2017
Last Verified: June 2017

Keywords provided by Michael Benatar, University of Miami:
genetics
biomarkers
pre-symptomatic
natural history

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
 Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases